Tirzepatide - 40mg

Tirzepatide engages two gut-hormone receptors at once: GIP and GLP-1. By targeting both pathways, it produces a broader incretin signalling profile than single-pathway agonists, making it a key reference compound for researchers studying receptor synergy, signalling bias, and comparative pharmacology against GLP-1-only molecules like semaglutide.

Tirzepatide has a deep and continually expanding clinical evidence base, with authorisation as a medicine in multiple jurisdictions. Research continues into cardiovascular disease, heart failure with preserved ejection fraction, sleep apnoea, and hepatic conditions.

Tirzepatide has been the subject of two flagship Phase 3 programmes — SURPASS (type 2 diabetes) and SURMOUNT (weight management):
Glycaemic control: HbA1c reductions of approximately 1.9–2.6% across the five SURPASS trials over 40–52 weeks.
Body weight: Reductions of approximately 6.6–13.9% in SURPASS, with further reductions in the SURMOUNT obesity programme.
Head-to-head against semaglutide: SURPASS-2 reported greater reductions in both HbA1c and body weight across all three tirzepatide doses (5 mg, 10 mg, 15 mg).
Cardiometabolic markers: Improvements in systolic blood pressure, lipid profile, and inflammatory markers.
Hepatic research: Active investigation in NAFLD and NASH.
Ongoing trials: SURPASS-CVOT and SUMMIT continue to generate cardiovascular and heart failure data.